🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

BTIG sees Carisma Therapeutics as 'undervalued', starts shares coverage with buy

Published 04/11/2024, 09:08 PM
CARM
-
MRNA
-

On Thursday, BTIG initiated coverage on Carisma Therapeutics Inc (NASDAQ: CARM), a clinical-stage cell therapy company, with a Buy rating and a price target of $6.00. Carisma Therapeutics is focused on the development of macrophage therapies for treating both oncology and non-oncology indications. The company's approach to solid tumors aims to utilize macrophages' natural abilities to recruit and stimulate immune cells, thereby promoting long-lasting immune responses.

The lead program of Carisma Therapeutics, CT-0525, targets refractory or relapsed HER2+ solid tumors. The company anticipates releasing monotherapy data from this program by the end of 2024, with combination therapy data involving pembrolizumab expected in the first half of 2025. These upcoming clinical milestones are seen as significant catalysts for the company's growth.

Moreover, Carisma's collaboration with Moderna (NASDAQ:MRNA) on the development of in-vivo macrophage therapies further underscores the potential of their technology. This partnership is viewed as a validation of Carisma's innovative approach to cell therapy.

In addition to its oncology programs, Carisma Therapeutics is also exploring treatments for fibrosis. Although this early-stage program carries both high risk and high reward, preclinical data is anticipated in the second quarter of 2024. The company's diverse portfolio of treatments and the expected clinical data release serve as a basis for the positive outlook.

BTIG's analysis suggests that Carisma Therapeutics is currently undervalued when compared to its cell therapy peers. The firm also highlights that Carisma has sufficient funding to continue its operations into the third quarter of 2025. With three clinical catalysts expected within the next 12 to 18 months, there is potential for additional upside from the company's in-vivo macrophage partnership and its fibrosis programs.

InvestingPro Insights

As Carisma Therapeutics Inc (NASDAQ: CARM) progresses with its innovative macrophage therapies, the financial landscape of the company provides additional context for investors. With a market capitalization of $79.35 million and a notable revenue growth of 51.71% in the last twelve months as of Q4 2023, Carisma demonstrates a capacity for expansion despite its challenges. The company's cash position is also a point of interest, as it holds more cash than debt, providing some financial stability.

InvestingPro Tips highlight that Carisma Therapeutics is trading at a low revenue valuation multiple and has a high shareholder yield, suggesting that the stock may be undervalued. Analysts have also revised their earnings upwards for the upcoming period, indicating potential optimism in the company's financial performance. However, it's important to note that Carisma is not expected to be profitable this year and has been quickly burning through cash, which could be a concern for long-term sustainability.

For investors seeking a more in-depth analysis, InvestingPro provides additional insights into Carisma Therapeutics. There are 13 more InvestingPro Tips available that could further inform your investment decisions. To explore these tips and gain a comprehensive understanding of Carisma's financial health and prospects, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/CARM.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.